HNGE · Hinge Health, Inc.

Current Thesis

The digital-MSK profitability re-rate cleared its overhead and re-accelerated. After the May 5 Q1 beat-and-raise, HNGE spent late May testing the $62.18 August-2025 all-time high; in the first week of June it broke through to fresh highs, printing $66.55 intraday and closing $63.62 on 2026-06-05 (+28.7% over 30 days). The breakout candle's igniter was a Canaccord Genuity PT raise to $65 on 2026-06-04, which drove a +4.5% session on 2026-06-05. The prior week's double-top read is void the breakout triggered. The leg is accelerating, with two caveats: the move is extended and well-circulated on the sell-side, and insiders are distributing into it.

Bull Case

• Breakout confirmed: closed $63.62 (2026-06-05) and ~$64.58 (2026-06-06), above the $62.18 ATH (2025-08-18) that capped the tape for nine months; 52-wk high now $66.55.
• Q1 FY2026 (2026-05-05): revenue $182.3M, +47% YoY; EPS $0.45 vs $0.12 consensus (275% beat); gross margin 85%; operating margin ~25%.
• Beat-and-raise still in force: FY2026 guide ~$801M (+40%); Q2 guide $194-196M (+40% midpoint); LTM calculated billings +52% YoY to $769.9M; clients +23% YoY to 2,849.
• Sell-side chasing two months past the print: Canaccord $63→$65 Buy (2026-06-04), the latest after the post-Q1 PT wall (Piper $95, Citizens $80 set 2026-05-07).
• Profitable compounder: forward P/E ~23.5, ~$407M cash, repurchased 2.5M shares ($105M) in Q1 funded growth, not a cash-burn IPO name.
• Optionality: FDA-cleared Enso migraine program landed 125+ clients / ~2M eligible lives within weeks of launch a 2027 TAM call option that costs nothing in the 2026 model.

Bear Case

• Insider distribution straight into the breakout: co-founder/exec-chairman Gabriel Mecklenburg sold 83,334 sh @ $60.22 (2026-06-01, $5.0M) and 50,000 sh @ $65.54 (2026-06-05, $3.28M); Bessemer funds (dir. Elliott Robinson) sold 2026-06-01/02 at ~$60-61; ~504,600 sh / ~$26.6M of insider sales over the trailing 90 days. 10b5-1 plans, but the cadence rose with the price.
• Price leads the targets: at ~$64 it trades at or above most published PTs (Canaccord $65; aggregator consensus spans ~$59-71), leaving the $95 Piper high as the main modeled upside.
• Catalyst vacuum: nothing hard-dated until the Q2 print on 2026-08-04 (~58 days out); the breakout must hold on momentum alone through the summer.
• Extension: +28.7% in 30 days into price-discovery air above $66.55; the re-rate from the $40s already fired on the May print.
• Competition: Sword Health (~22% share) bought Kaia Health ($285M) and is a 2026 IPO watch; Omada (OMDA) is public enterprise renewal pricing pressure building.
• Migraine is a 2027 number: management guides minimal 2026 contribution, so near-term it is story, not revenue.

Setup & Price Structure

• Price ~$63.62 (2026-06-05 close) / ~$64.58 (2026-06-06); after-hours $63.78; 52-wk range $30.08-$66.55; market cap ~$4.92B.
• Structure: IPO 2025-05-21 at ~$32 → nine-month base in the $30s-$40s → May 5 earnings breakout → June breakout through the $62.18 ATH. Higher-high sequence intact.
• Levels: breakout pivot / new support $62.18 (old ATH); May post-earnings shelf $50-52; rising 20-week EMA est. ~$50-52 after the run; overhead is open price discovery above $66.55.
• Stage: ACCELERATING the breakout re-fired the leg the prior week's read had written off. New highs, fresh PT, and the +4.5% upgrade session align.
• Beginner-trap matrix: not earnings <3d (Aug 4); not averaging-down territory. The live risk is chasing extended new-high air (+28.7%/30d) with insiders selling into it and price already at most targets

Catalyst Calendar (next 30 days)

• No hard-dated company catalyst inside the window. Q2 FY2026 print is 2026-08-04 (~8:00 PM UTC) outside 30 days.
• Ongoing: sell-side PT revisions (Canaccord acted 2026-06-04; watch Piper/Citizens/Stifel for follow-through above $65).
• Ongoing: Form 4 insider sales under active 10b5-1 plans (Mecklenburg, Bessemer, CFO Budge) track whether the pace rises further into strength or converts to discretionary blocks.
• Theme read: digital-health / wellness-tech-IPO-class sentiment (Oura IPO chatter, 2026-05-22); watch Sword Health IPO timing as peer-confirmation or a supply event.

What Would Change Our Mind

• Trend break: a weekly close back below ~$58 fails the breakout and surrenders the $62.18 prior-ATH shelf; loss of the rising 20-week EMA (~$50-52) ends the leg.
• Fundamental break: Q2 (2026-08-04) revenue below the $194M guide floor, or any walk-back of the 26% FY op-margin target.
• Flow break: 10b5-1 insider selling converting to discretionary block sales, or net dollar retention guidance softening on competitive renewals.
• Theme break: digital-MSK flips SATURATED on a Sword Health IPO that floods supply or undercuts enterprise pricing.

Correlation Notes

• Direct peers: Sword Health (private, ~22% MSK share, Kaia $285M deal, 2026 IPO watch), Omada Health (OMDA). A digital-MSK/virtual-care cluster a Sword IPO is the key peer-confirmation or supply event.
• Theme basket: wellness-tech IPO class of 2025 (Oura chatter 2026-05-22) re-rating from busted toward investable; HNGE is the profitable bellwether of that cohort.
• Macro: long-duration profitable growth sensitive to the rate path; a renewed yield spike compresses the ~23.5x forward multiple. Beta to growth-tech (ARKK-style) and the broad healthcare-tech tape.
• Idiosyncratic: institutionally-driven, sell-side-led name (not a retail-squeeze ticker) moves on PT revisions and enterprise client adds more than on retail flow.